Transcriptomic signatures of treatment response to the combination of escitalopram and memantine or placebo in late-life depression.

ABSTRACT: Drugs that target glutamate neuronal transmission, such as memantine, offer a novel approach to the treatment of late-life depression, which is frequently comorbid with cognitive impairment. The results of our recently published double-blind, randomized, placebo-controlled trial of escitalopram or escitalopram/memantine in late-life depression with subjective memory complaints (NCT01902004) indicated no differences between treatments in depression remission, but additional benefits in cognition at 12-month follow-up with combination treatment. To identify pathways and biological functions uniquely induced by combination treatment that may explain cognitive improvements, we generated transcriptional profiles of remission compared with non-remission from whole blood samples. Remitters to esc

SUBMITTER: Grzenda A 

PROVIDER: S-EPMC9922535 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature